Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials

Nicolino Ruperto*, Hermine I. Brunner, Pierre Quartier, Tamàs Constantin, Nico M. Wulffraat, Gerd Horneff, Ozgur Kasapcopur, Rayfel Schneider, Jordi Anton, Judith Barash, Reinhard Berner, Fabrizia Corona, Ruben Cuttica, Marine Fouillet-Desjonqueres, Michel Fischbach, Helen E. Foster, Dirk Foell, Sebastião C. Radominski, Athimalaipet V. Ramanan, Ralf TrauzeddelErbil Unsal, Jérémy Levy, Eleni Vritzali, Alberto Martini, Daniel J. Lovell

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science